查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014449

DNA檢測套組市場：按檢測類型、技術、產品類型和最終用戶分類－全球市場預測（2026-2032年）

DNA Test Kits Market by Test Type, Technology, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年DNA檢測套組市場價值為13.5億美元，預計到2026年將成長至16.1億美元，複合年成長率為19.49%，到2032年將達到46.9億美元。

主要市場統計數據
基準年 2025 13.5億美元
預計年份：2026年 16.1億美元
預測年份 2032 46.9億美元
複合年成長率 (%) 19.49%

DNA檢測套組的策略性引入：消費者購買因素、臨床檢驗流程、法規環境和商業化考量

DNA檢測套組市場正處於技術快速發展和用戶期望不斷變化交匯的階段，這給產品開發人員、臨床採用者和銷售團隊帶來了複雜的挑戰。本文概述了影響該領域的關鍵因素，首先介紹了目前種類繁多的檢測類型，從祖源和親子鑑定到攜帶者篩檢和高級健康風險評估。隨著消費者對個人基因組學的興趣日益成長，對臨床級表現、可重複結果以及清晰的解讀和後續流程的需求也隨之增加。

在人工智慧、多組體學、消費者賦權和不斷發展的數據管治的推動下，DNA 檢測正在迅速從研究轉向常規醫療保健。

DNA檢測套組的市場格局正經歷一場變革性的轉變，重塑著供需動態。技術融合，特別是高通量定序和先進分析技術的整合，使得以往僅限於專業實驗室的檢測方式得以進入更廣泛的臨床和消費管道。因此，DNA檢測正從短暫的好奇心轉變為預防醫學和藥物治療決策中的實用環節。藥物藥物基因體學和遺傳易感性評估在常規臨床工作流程中日益成長的效用，進一步推動了這一發展趨勢。

研究 2025 年美國關稅對供應鏈、製造決策、監管協調和臨床服務的累積影響。

美國在2025年實施的關稅政策為DNA檢測套組的生產和銷售企業帶來了新的業務限制，其累積影響波及採購、生產和服務交付等各個環節。進口試劑、耗材和專用設備的關稅成本壓力促使企業重新評估其供應商組合，並尋求替代籌資策略。為此，一些製造商加快了關鍵零件的在地採購，而另一些製造商則調整了定價模式，以維持利潤率並繼續投資研發。

整合測試類型、技術、產品類別和最終用戶行為等關鍵細分洞察，對於制定有針對性的策略和發展至關重要。

精細化的市場區隔框架對於將多樣化的使用者需求轉化為產品和商業優先事項至關重要。就檢測類型而言，市場涵蓋祖源分析、攜帶者檢測（進一步細分為篩檢和產前攜帶者篩檢）、健康風險檢測（包括遺傳疾病易感性檢測）、生活方式和健康相關應用，以及藥物基因體學和親子鑑定服務（區分資訊性親子鑑定和法律親子鑑定）。每種檢測類型都有其獨特的臨床效用、檢體處理要求和監管要求，這些都體現在檢驗方法和訊息策略的製定中。

區域分析比較了美洲、歐洲、中東和非洲以及亞太地區，突顯了監管差異、擴散模式和供應韌性。

區域趨勢對DNA檢測套組的研發、監管和商業化有顯著影響，每個地區都擁有其獨特的優勢和限制因素。在美洲，強勁的消費者需求和完善的臨床遺傳學基礎設施支撐著多元化的銷售管道，涵蓋從直接面對消費者銷售到與醫院檢查室服務的整合。這種環境促進了快速創新和擴充性的分銷，同時也要求仔細考慮支付方的要求以及各州之間細微的監管差異。

透過垂直整合、臨床夥伴關係、智慧財產權管理和服務差異化，塑造 DNA檢測套組公司的企業策略和合作夥伴關係。

DNA檢測套組生態系統中的企業正透過結合技術領先優勢、策略夥伴關係和營運整合來實現差異化競爭。市場領導和新興挑戰者都在尋求垂直整合，以確保關鍵試劑和設備的供應；而其他企業則專注於服務差異化，提供解讀平台、臨床醫生支援服務和縱向數據產品。與臨床檢查室、醫療保健系統和數位健康平台的夥伴關係，能夠擴大分銷範圍並加速臨床檢驗流程。

為行業領導者提供實用建議，以最佳化產品藍圖、加強價值鏈、與監管機構合作以及使定價與臨床價值保持一致。

產業領導者應採取一系列切實可行的措施，在保持臨床可靠性和消費者信心的同時，實現長期價值。首先，應優先考慮模組化產品架構，使其能夠在專業檢測和自測模式之間快速切換，從而無需徹底重新設計即可應對不斷變化的監管要求和用戶偏好。其次，應透過策略性雙重採購、庫存避險以及關鍵試劑和耗材的選擇性垂直整合來增強價值鏈韌性，從而最大限度地減少中斷並保持交貨性能。

這種高度透明的調查方法詳細說明了初步訪談、二次檢驗驗證、專家檢驗和品管，以確保調查方法的嚴謹性。

本報告基於多方面的研究途徑，整合了來自一手訪談的洞見、對二手文獻的回顧以及系統的專家檢驗，以確保分析的嚴謹性。一手研究包括對實驗室負責人、臨床醫生、採購經理和產品經理進行詳細訪談，以了解營運限制和推廣應用的促進因素。這些定性資訊用於建構假設，並確定定量後續研究的優先領域。

為了幫助 DNA 檢測領域的相關人員制定策略重點，我們綜合考慮了技術、監管和商業性因素，並得出了一些結論。

總之，本文整合了現代DNA檢測套組開發和應用過程中湧現的技術、監管和商業性主題。定序和分析技術的進步不斷擴展基因檢測的臨床效用，而日益嚴格的資料管治和監管審查也提高了證據產生的門檻。這些趨勢共同作用，有利於那些能夠將嚴謹的分析檢驗、以使用者為中心的報告和安全的資料管理結合的機構。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：DNA檢測套組市場：依檢測類型分類

  • 祖先
  • 基因帶原檢測
    • 懷孕前攜帶者篩檢
    • 產前攜帶者篩檢
  • 健康風險
    • 易患遺傳性疾病
    • 生活方式與健康
    • 藥物基因體學
  • 親子鑑定
    • 親子鑑定僅用於提供信息
    • 親子鑑定

第9章：DNA檢測套組市場：依技術分類

  • 微陣列
  • PCR
  • 定序

第10章：DNA檢測套組市場：依產品類型分類

  • 商用套件
    • 臨床診斷試劑盒
    • 研究工具包
  • 自測檢測套組

第11章 DNA檢測套組市場：依最終用戶分類

  • 一般消費者
  • 醫護人員
    • 診斷和檢測機構
    • 醫院、診所
  • 研究機構

第12章 DNA檢測套組市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 DNA檢測套組市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 DNA檢測套組市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國DNA檢測套組市場

第16章：中國DNA檢測套組市場

第17章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • 23andMe, Inc.
  • AB ANALITICA srl
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Ancestry.com LLC
  • Bio-Rad Laboratories, Inc.
  • BioNano Genomics, Inc.
  • CyberGene AB
  • FitnessGenes Limited
  • FUTURA GENETICS
  • Illumina, Inc.
  • Indus Health Plus Pvt Ltd
  • Living DNA Ltd,
  • MyHeritage Ltd.
  • Premas Lifesciences Pvt. Ltd.
  • QIAGEN NV
  • Roche Diagnostics
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific
  • Veritas Genetics International Limited
Product Code: MRR-4348D129FA45

The DNA Test Kits Market was valued at USD 1.35 billion in 2025 and is projected to grow to USD 1.61 billion in 2026, with a CAGR of 19.49%, reaching USD 4.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.35 billion
Estimated Year [2026] USD 1.61 billion
Forecast Year [2032] USD 4.69 billion
CAGR (%) 19.49%

Strategic introduction to DNA test kits examining consumer drivers, clinical validation pathways, regulatory context and commercialization considerations

The DNA test kit landscape is at the intersection of rapid technological progress and shifting user expectations, creating a complex environment for product developers, clinical adopters and commercial teams. This introduction frames the critical forces shaping the sector, beginning with the broad spectrum of test types that now extend from ancestry and paternity to carrier screening and sophisticated health-risk assessments. As consumer interest in personal genomics grows, so does the demand for clinical-grade performance, reproducible results, and clear pathways for interpretation and follow-up.

In parallel, technology choices-from microarrays to PCR workflows and sequencing platforms-determine not only analytic sensitivity but also cost structure, throughput and the potential for downstream integration with electronic health systems. Product strategies must account for the divergent needs of professional users, including clinical diagnostic laboratories and research institutions, as well as self-testing markets where ease of use and privacy assurances dominate decision criteria. Transitioning from prototype to market requires careful navigation of regulatory expectations, lab accreditation standards and payer perspectives, all while maintaining a focus on data security.

Throughout this report, the introduction establishes the conceptual framework used to evaluate innovations, competitive dynamics and commercial viability. It emphasizes the need for clear analytical validation, robust operational design and alignment between product claims and user expectations to ensure long-term adoption and trust in genetic testing.

Rapid transformative shifts reshaping DNA testing from research to routine care driven by AI, multi-omics, consumer empowerment and evolving data governance

The landscape of DNA test kits is undergoing transformative shifts that reconfigure both supply and demand dynamics. Technological convergence, particularly the integration of higher-throughput sequencing and advanced analytics, is enabling test formats that were previously confined to specialist laboratories to enter broader clinical and consumer channels. As a result, testing is moving from episodic curiosity toward actionable components of preventive care and pharmacotherapy decision making. This evolution is reinforced by the rising utility of pharmacogenomics and genetic predisposition assessments in routine clinical workflows.

Concurrently, artificial intelligence and machine learning are improving variant interpretation and phenotype linkage, creating opportunities to package more insightful, clinician-friendly reports. These gains are tempered by heightened attention to data governance and privacy, which are prompting firms to adopt more rigorous consent frameworks and secure data handling practices. Regulatory attention is intensifying as agencies refine guidance on direct-to-consumer disclosures and clinical claims, which increases the premium on validated evidence and transparent performance metrics.

Finally, consumer expectations have shifted toward integrated services that combine testing with counseling, longitudinal follow-up and digital health interfaces. This creates a strategic imperative for firms to form cross-sector collaborations spanning clinical networks, payers and digital health platforms, enabling an end-to-end experience that bridges raw data and actionable recommendations while maintaining trust and clinical relevance.

Exploration of cumulative effects from United States tariffs in 2025 on supply chains, manufacturing decisions, regulatory alignment and clinical service

United States tariff actions in 2025 introduced a new operating constraint for companies producing and distributing DNA test kits, with cumulative effects that ripple across procurement, manufacturing and service delivery. Tariff-induced cost pressures on imported reagents, consumables and specialized instrumentation have incentivized firms to reassess supplier portfolios and pursue alternative sourcing strategies. In response, some manufacturers accelerated localization of critical components while others restructured pricing models to preserve margins and sustain R&D investments.

Supply chain adjustments have also affected inventory strategies and lead-time management, prompting a shift toward dual sourcing and increased onshore inventory buffers for mission-critical items. These operational changes have implications for turnaround times and laboratory throughput, and have elevated contract management as a core capability. At the same time, tariffs have catalyzed conversations with regulators and payers about the downstream impact on access and affordability, especially where cost increases could deter clinician ordering or consumer uptake.

Strategically, the tariff environment has accentuated the importance of design-for-manufacturability choices that reduce dependence on tariff-exposed inputs, and it has increased the appeal of vertically integrated models that control more of the value chain. In short, the tariff landscape of 2025 has been a catalyst for supply chain resilience strategies, procurement diversification and closer alignment between commercial pricing and operational realities.

Key segmentation insights synthesizing test types, technologies, product classifications and end user behaviors to shape targeted strategies and development

A nuanced segmentation framework is essential to translate heterogeneous user needs into product and commercial priorities. Considering test type, the market spans ancestry assays, carrier testing segmenting further into preconception carrier screening and prenatal carrier screening, health risk testing that includes genetic disease predisposition, lifestyle and wellness applications as well as pharmacogenomics, and paternity offerings that differentiate informational paternity from legal paternity scenarios. Each test type carries distinct clinical utility, sample handling requirements and regulatory expectations, which inform validation approaches and messaging strategies.

Technology choice similarly shapes performance and cost trade-offs. Microarray platforms offer efficient genotyping for targeted applications, PCR methods provide rapid, focused assays suited to single-gene or targeted variant detection, and sequencing technologies enable comprehensive variant discovery and copy-number resolution for broader clinical interpretations. Product type segmentation separates professional use kits-further divided into clinical diagnostics kits and research use only kits-from self-testing kits, creating divergent product development pathways and distribution channels.

End user distinctions influence packaging, service levels and commercialization approaches. Individual consumers require clarity, privacy assurances and simplified reporting, while medical professionals, including diagnostic laboratories and hospitals and clinics, demand rigorous analytic validation, chain-of-custody controls and integration with clinical workflows. Research institutes prioritize modularity and data access for hypothesis-driven studies. Mapping these dimensions against one another reveals where clinical demand, regulatory burden and commercial opportunity align, guiding prioritization for R&D, pricing and market entry strategies.

Regional insights comparing Americas, Europe Middle East and Africa, and Asia-Pacific to highlight regulatory variation, adoption patterns and supply resilience

Regional dynamics significantly influence how DNA test kits are developed, regulated and commercialized, with each geography presenting unique advantages and constraints. In the Americas, robust consumer demand and established clinical genetics infrastructure support diverse channels from direct-to-consumer offerings to integrated hospital laboratory services. This environment rewards rapid innovation and scalable distribution, but also requires careful navigation of payer requirements and state-level regulatory nuances.

In Europe, Middle East & Africa, the regulatory and reimbursement landscape displays substantial variation across countries, which encourages localized regulatory strategies and region-specific evidence generation to support clinical adoption. Data protection standards and cross-border data transfer considerations are particularly salient, prompting firms to invest in compliant data architectures and localized interpretation services. Supply chain pathways and reimbursement models in this region often call for flexible commercial approaches that can adapt to diverse health system structures.

Asia-Pacific exhibits a mix of market maturity, with some markets characterized by strong government-led genomic initiatives and others by rapidly growing consumer segments. Manufacturing capacity in the region has been expanding, offering opportunities to source components closer to end markets and to partner with regional clinical networks for validation studies. Across all regions, success depends on aligning technical validation and regulatory submissions with local expectations while tailoring go-to-market models to account for variations in clinician behavior, consumer trust and reimbursement mechanisms.

Corporate strategies and alliances shaping DNA test kit companies through vertical integration, clinical partnerships, IP stewardship and service differentiation

Companies operating in the DNA test kit ecosystem are differentiating through a combination of technology leadership, strategic partnerships and operational integration. Market leaders and emerging challengers alike are pursuing vertical integration to secure supply of critical reagents and instrumentation, while others focus on service differentiation by offering interpretation platforms, clinician support services and longitudinal data products. Partnerships with clinical laboratories, healthcare systems and digital health platforms amplify distribution reach and accelerate clinical validation pathways.

Intellectual property stewardship remains a core strategic asset, influencing competitive positioning and licensing strategies. Firms that balance proprietary assay development with interoperable reporting standards often find broader clinical adoption. Additionally, pricing strategies are evolving to reflect bundled service models where testing is paired with counseling, follow-up care or integration into digital care pathways. This shift increases the emphasis on demonstrating clinical and economic value to payers and providers.

Mergers and acquisitions continue to be a consolidation mechanism for capabilities such as bioinformatics, sample logistics and regulatory expertise. Companies that invest in scalable laboratory operations, robust quality management systems and data governance frameworks are better positioned to translate scientific advances into reliable, reproducible products that meet the diverse needs of clinical and consumer markets.

Actionable recommendations for industry leaders to optimize product roadmaps, strengthen supply chains, engage regulators and align pricing to clinical value

Industry leaders should adopt a pragmatic set of actions to capture long-term value while preserving clinical credibility and consumer trust. First, prioritize modular product architectures that allow rapid adaptation between professional and self-testing formats, enabling firms to respond to changing regulatory requirements and user preferences without full redesign. Second, strengthen supply chain resilience through strategic dual sourcing, inventory hedging and selective vertical integration for critical reagents and consumables to minimize disruption and preserve fulfillment performance.

Third, engage proactively with regulators and payers by generating clinical utility evidence and economic narratives that connect test results to actionable care pathways. Early engagement helps clarify submission expectations and accelerates coverage conversations. Fourth, invest in secure, privacy-first data platforms and transparent consent models that build user confidence and facilitate appropriate data sharing for research and clinical follow-up. Fifth, pursue partnerships that expand clinical validation opportunities, such as collaborations with diagnostic laboratories and specialty clinics, to accelerate adoption and incorporate clinician feedback into product refinement.

Finally, align commercial models to demonstrate clear value to clinicians and consumers, using outcome-based narratives where possible. These combined steps will help organizations balance near-term operational challenges with sustainable positioning for the ongoing clinical integration of genomic testing.

Transparent research methodology detailing primary interviews, secondary triangulation, expert validation and quality controls to ensure methodological rigor

This report is grounded in a multi-method research approach that integrates primary interview insights, secondary literature review and systematic expert validation to ensure analytical rigor. Primary research included in-depth interviews with laboratory directors, clinicians, procurement leaders and product managers to capture real-world operational constraints and adoption drivers. These qualitative inputs informed hypothesis generation and prioritized areas for quantitative follow-up.

Secondary research synthesized peer-reviewed literature, regulatory guidance documents and company disclosures to map technology attributes, validation expectations and product archetypes. Data triangulation techniques reconciled divergent findings from multiple sources, and analytic frameworks were applied to segment the market along test type, technology, product type and end user dimensions. Expert panels provided critical review of assumptions, ensuring that interpretive judgments aligned with current practice and emerging trends.

Quality control procedures included cross-checking technical claims, validating terminology consistency across regions and documenting methodological limitations. Where data gaps existed, the methodology identifies recommended follow-up studies and bespoke analyses that can refine strategic decisions. The approach is designed to be transparent and reproducible, supporting confident application of insights to product development, regulatory planning and go-to-market execution.

Concluding perspectives synthesizing technological, regulatory and commercial drivers to inform strategic priorities for stakeholders in DNA testing

The conclusion integrates the technological, regulatory and commercial themes that emerge from contemporary DNA test kit development and deployment. Advances in sequencing and analytics are broadening the clinical utility of genetic testing, while increased scrutiny on data governance and regulatory claims is raising the bar for evidence generation. Together, these dynamics favor organizations that combine rigorous analytic validation with user-centered reporting and secure data practices.

Commercially, success will hinge on demonstrating clinical relevance through partnerships with laboratories and health systems, and on developing commercial models that align price with demonstrated outcomes. Operational resilience-particularly in supply chain design and component sourcing-remains a critical determinant of sustained service quality. Regional heterogeneity requires tailored regulatory strategies and localized engagement plans to translate global capabilities into local adoption.

In sum, stakeholders who integrate technical excellence, regulatory foresight and pragmatic commercial execution will be best positioned to translate genomic innovation into repeatable, scalable clinical and consumer services. The strategic priorities identified here provide a roadmap for converting scientific promise into durable market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Test Kits Market, by Test Type

  • 8.1. Ancestry
  • 8.2. Carrier Testing
    • 8.2.1. Preconception Carrier Screening
    • 8.2.2. Prenatal Carrier Screening
  • 8.3. Health Risk
    • 8.3.1. Genetic Disease Predisposition
    • 8.3.2. Lifestyle And Wellness
    • 8.3.3. Pharmacogenomics
  • 8.4. Paternity
    • 8.4.1. Informational Paternity
    • 8.4.2. Legal Paternity

9. DNA Test Kits Market, by Technology

  • 9.1. Microarray
  • 9.2. PCR
  • 9.3. Sequencing

10. DNA Test Kits Market, by Product Type

  • 10.1. Professional Use Kits
    • 10.1.1. Clinical Diagnostics Kits
    • 10.1.2. Research Use Only Kits
  • 10.2. Self Testing Kits

11. DNA Test Kits Market, by End User

  • 11.1. Individuals
  • 11.2. Medical Professionals
    • 11.2.1. Diagnostic Laboratories
    • 11.2.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. DNA Test Kits Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA Test Kits Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA Test Kits Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA Test Kits Market

16. China DNA Test Kits Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 23andMe, Inc.
  • 17.6. AB ANALITICA srl
  • 17.7. Abbott Laboratories
  • 17.8. Agilent Technologies Inc.
  • 17.9. Ancestry.com LLC
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. BioNano Genomics, Inc.
  • 17.12. CyberGene AB
  • 17.13. FitnessGenes Limited
  • 17.14. FUTURA GENETICS
  • 17.15. Illumina, Inc.
  • 17.16. Indus Health Plus Pvt Ltd
  • 17.17. Living DNA Ltd,
  • 17.18. MyHeritage Ltd.
  • 17.19. Premas Lifesciences Pvt. Ltd.
  • 17.20. QIAGEN N.V.
  • 17.21. Roche Diagnostics
  • 17.22. Siemens Healthcare GmbH
  • 17.23. Thermo Fisher Scientific
  • 17.24. Veritas Genetics International Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA TEST KITS MARKET SIZE, BY ANCESTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA TEST KITS MARKET SIZE, BY PRECONCEPTION CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA TEST KITS MARKET SIZE, BY PRENATAL CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA TEST KITS MARKET SIZE, BY GENETIC DISEASE PREDISPOSITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA TEST KITS MARKET SIZE, BY LIFESTYLE AND WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA TEST KITS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA TEST KITS MARKET SIZE, BY INFORMATIONAL PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA TEST KITS MARKET SIZE, BY LEGAL PATERNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA TEST KITS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA TEST KITS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA TEST KITS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSTICS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH USE ONLY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA TEST KITS MARKET SIZE, BY SELF TESTING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA TEST KITS MARKET SIZE, BY INDIVIDUALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DNA TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. G7 DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 206. G7 DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 216. NATO DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DNA TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA DNA TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA DNA TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA DNA TEST KITS MARKET SIZE, BY CARRIER TESTING, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA DNA TEST KITS MARKET SIZE, BY HEALTH RISK, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA DNA TEST KITS MARKET SIZE, BY PATERNITY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA DNA TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DNA TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DNA TEST KITS MARKET SIZE, BY PROFESSIONAL USE KITS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DNA TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DNA TEST KITS MARKET SIZE, BY MEDICAL PROFESSIONALS, 2018-2032 (USD MILLION)